T.MAN Pharmaceutical Public Company Limited

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR carries a market capitalization of 4.36B, placing it among publicly traded companies globally. Its enterprise value stands at 4.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

T.MAN Pharmaceutical Public Company Limited NVDR's next confirmed earnings release is scheduled for November 18, 2026.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR has 400.00M shares outstanding.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR trades at a trailing price-to-earnings ratio of 8.63. The price-to-sales ratio is 1.68, and the price-to-book ratio stands at 1.98.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR trades at an EV/EBITDA multiple of 5.83 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.71 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.14 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. T.MAN Pharmaceutical Public Company Limited NVDR trades at an EV/FCF ratio of 42.53, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 4.44B versus a market cap of 4.36B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR maintains a current ratio of 1.56, meaning it holds 1.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 42.65, indicating elevated leverage, while an interest coverage ratio of 36.58 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR posted a return on equity (ROE) of 24.59, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 17.10 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 13.84, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.26, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.31 indicates how many times T.MAN Pharmaceutical Public Company Limited NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR recorded 95.34M in income tax expense. That works out to an effective tax rate of 15.84, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 601.93M, leaving 506.59M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, T.MAN Pharmaceutical Public Company Limited NVDR's stock has declined approximately 9.65% over the past 52 weeks. The 50-day moving average sits at 10.47, while the 200-day moving average is 11.30.

Over the twelve months ended June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR generated 2.60B in revenue and converted that into 506.59M in net income, yielding earnings per share of 1.26. EBITDA reached 762.64M, while operating income came in at 552.37M.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR holds 856.12M in cash and equivalents against 938.75M in total debt, resulting in a net debt position of 367.57M. Total book value stands at 2.20B, with working capital of 870.76M providing operational flexibility.

T.MAN Pharmaceutical Public Company Limited NVDR produced 406.12M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -319.21M in capital expenditures, free cash flow totaled 86.90M - equivalent to 0.22 per share.

Over the twelve months ended June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR posted a gross margin of 45.09, reflecting its pricing power and cost economics. The operating margin of 21.22 and net profit margin of 19.46 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR paid dividends of 0.56 per share. The dividend payout ratio of 44.21 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.99, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 7.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to T.MAN Pharmaceutical Public Company Limited NVDR shareholders.

As of June 30, 2026, T.MAN Pharmaceutical Public Company Limited NVDR has an Altman Z-Score of 3.17, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.